nach oben

Head and Neck Pathology

Erschienen in:

28.02.2017 | Original Paper

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas

verfasst von: Michelle D. Williams, Arthur S. Tischler

Erschienen in: Head and Neck Pathology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Updated editions of The World Health Organization Classification of Tumours Pathology & Genetics for both Head and Neck Tumours and Tumours of Endocrine Organs took place in 2016 based on consensus conferences. These editions present unification of concepts in paragangliomas and highlight expanding knowledge of their etiology. There is a major emphasis in the new bluebooks on familial/syndromic paragangliomas, representing ~40% of all head and neck paragangliomas. Ancillary use of immunohistochemical evaluation, specifically of SDHB, allows the pathologist to screen for a large subset of these potentially hereditary cases. In addition, similarly to other neuroendocrine tumors, paragangliomas are now considered to represent a continuum of risk, and are assessed in terms of risk stratification. Tumors with SDHB mutations pose the highest risk for metastasis. There is currently no validated or endorsed histologic grading system. Paragangliomas remain tumors of undetermined biologic potential and should not be termed benign.

Pacak K, Wimalawansa SJ. Pheochromocytoma and paraganglioma. Endocr Pract. 2015;21:406–12.CrossRefPubMed

Boedeker CC, Hensen EF, Neumann HP, Maier W, van Nederveen FH, Suarez C, Kunst HP, Rodrigo JP, Takes RP, Pellitteri PK, Rinaldo A, Ferlito A. Genetics of hereditary head and neck paragangliomas. Head Neck. 2014;36:907–16.CrossRefPubMed

Dahia PL. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108–19.CrossRefPubMed

Castro-Vega LJ, Letouze E, Burnichon N, Buffet A, Disderot PH, Khalifa E, Loriot C, Elarouci N, Morin A, Menara M, Lepoutre-Lussey C, Badoual C, Sibony M, Dousset B, Libe R, Zinzindohoue F, Plouin PF, Bertherat J, Amar L, de Reynies A, Favier J, Gimenez-Roqueplo AP. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6044.CrossRefPubMedPubMedCentral

Fishbein L. Pheochromocytoma and paraganglioma: genetics, diagnosis, and treatment. Hematol Oncol Clin North Am. 2016;30:135–50.CrossRefPubMed

Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I, Abermil N, Inglada-Perez L, de Cubas AA, Amar L, Barontini M, de Quiros SB, Bertherat J, Bignon YJ, Blok MJ, Bobisse S, Borrego S, Castellano M, Chanson P, Chiara MD, Corssmit EP, Giacche M, de Krijger RR, Ercolino T, Girerd X, Gomez-Garcia EB, Gomez-Grana A, Guilhem I, Hes FJ, Honrado E, Korpershoek E, Lenders JW, Leton R, Mensenkamp AR, Merlo A, Mori L, Murat A, Pierre P, Plouin PF, Prodanov T, Quesada-Charneco M, Qin N, Rapizzi E, Raymond V, Reisch N, Roncador G, Ruiz-Ferrer M, Schillo F, Stegmann AP, Suarez C, Taschin E, Timmers HJ, Tops CM, Urioste M, Beuschlein F, Pacak K, Mannelli M, Dahia PL, Opocher G, Eisenhofer G, Gimenez-Roqueplo AP, Robledo M. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012;18:2828–37.CrossRefPubMed

Neumann HP, Sullivan M, Winter A, et al. Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites. J Clin Endocrinol Metab. 2011;96:E1279–E1282.CrossRefPubMed

Clark GR, Sciacovelli M, Gaude E, Walsh DM, Kirby G, Simpson MA, Trembath RC, Berg JN, Woodward ER, Kinning E, Morrison PJ, Frezza C, Maher ER. Germline FH mutations presenting with pheochromocytoma. J Clin Endocrinol Metab. 2014 Oct;99(10):E2046–E50.CrossRefPubMed

Fliedner S Hypoxia-inducible factor 2α mutation-related paragangliomas classify as discrete pseudohypoxic subcluster. Neoplasia. 2016;18:567–576.CrossRefPubMedPubMedCentral

10.

Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915–42.CrossRefPubMed

11.

Shankavaram U, Fliedner SM, Elkahloun AG, et al. Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia. 2013;15:435–47.CrossRefPubMedPubMedCentral

12.

Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, Yee HA, Brackmann DE, Slattery WH 3rd, Myers EN, Ferrell RE, Rubinstein WS. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002 Mar;39(3):178–83.CrossRefPubMedPubMedCentral

13.

Mayers JR, Vander Heiden MG. Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem Sci. 2015;40:130–40.CrossRefPubMedPubMedCentral

14.

Baysal BE, Maher ER: 15 years of paraganglioma: genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations. Endocr Relat Cancer. 2015;22:T71–82.CrossRef

15.

Haller F, Moskalev EA, Faucz FR, Barthelmess S, Wiemann S, Bieg M, Assie G, Bertherat J, Schaefer IM, Otto C, Rattenberry E, Maher ER, Strobel P, Werner M, Carney JA, Hartmann A, Stratakis CA, Agaimy A. Aberrant DNA hypermethylation of SDHC. a novel mechanism of tumor development in carney triad. Endocr Relat Cancer. 2014;21:567–77.CrossRefPubMedPubMedCentral

16.

Boikos SA, Xekouki P, Fumagalli E, et al. Carney triad can be (rarely) associated with germline succinate dehydrogenase defects. Eur J Hum Genet 2016;24:569–73.CrossRefPubMed

17.

Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011;35:1712–21.CrossRefPubMedPubMedCentral

18.

Williamson SR, Eble JN, Amin MB, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma. Mod Pathol 2015;28:80–94.CrossRefPubMed

19.

Gill AJ, Pachter NS, Chou A, et al. Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol. 2011;35:1578–85.CrossRefPubMed

20.

Dwight T, Mann K, Benn DE, et al. Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paraganglioma. J Clin Endocrinol Metab. 2013;98:E1103–E1108.CrossRefPubMed

21.

van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bruïne AP, Maher ER, Tissier F, Méatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, François J, de Herder WW, Peeters MP, van Linge A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, Dinjens WN. An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol. 2009;10(8):764–71.CrossRefPubMedPubMedCentral

22.

Gill AJ, Benn DE, Chou A, Clarkson A, Muljono A, Meyer-Rochow GY, Richardson AL, Sidhu SB, Robinson BG, Clifton-Bligh RJ. Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytoma syndromes. Hum Pathol. 2010;41(6):805–14. doi:10.1016/j.humpath.2009.12.005.CrossRefPubMed

23.

Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, Tischler AS, Tissier F, Volante M, Matias-Guiu X, Smid M, Favier J, Rapizzi E, Libe R, Currás-Freixes M, Aydin S, Huynh T, Lichtenauer U, van Berkel A, Canu L, Domingues R, Clifton-Bligh RJ, Bialas M, Vikkula M, Baretton G, Papotti M, Nesi G, Badoual C, Pacak K, Eisenhofer G, Timmers HJ, Beuschlein F, Bertherat J, Mannelli M, Robledo M, Gimenez-Roqueplo AP, Dinjens WN, Korpershoek E, de Krijger RR. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol. 2015;28(6):807–21.CrossRefPubMed

24.

Korpershoek E, Favier J, Gaal J, Burnichon N, van Gessel B, Oudijk L, Badoual C, Gadessaud N, Venisse A, Bayley JP, van Dooren MF, de Herder WW, Tissier F, Plouin PF, van Nederveen FH, Dinjens WN, Gimenez-Roqueplo AP, de Krijger RR. SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas. J Clin Endocrinol Metab. 2011;96(9):E1472–6.CrossRefPubMed

25.

Benn DE, Robinson BG, Clifton-Bligh RJ. 15 Years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1–5. Endocr Relat Cancer. 2015;22:T91–103.CrossRefPubMedPubMedCentral

26.

Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, Hoffman HT; American College of Surgeons Commission on Cancer; American Cancer Society. National cancer data base report on malignant paragangliomas of the head and neck. Cancer. 2002;94(3):730–7.CrossRefPubMed

27.

Sethi RV, Sethi RK, Herr MW, Deschler DG. Malignant head and neck paragangliomas: treatment efficacy and prognostic indicators. Am J Otolaryngol. 2013;34(5):431–8. doi:10.1016/j.amjoto.2013.03.010.CrossRefPubMed

28.

Ellis RJ, Patel D, Prodanov T, Nilubol N, Pacak K, Kebebew E. The presence of SDHB mutations should modify surgical indications for carotid body paragangliomas. Ann Surg. 2014;260(1):158–62.CrossRefPubMed

29.

Dénes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, Xekouki P, Moran L, Kumar A, Wassif C, Fersht N, Baldeweg SE, Morris D, Lightman S, Agha A, Rees A, Grieve J, Powell M, Boguszewski CL, Dutta P, Thakker RV, Srirangalingam U, Thompson CJ, Druce M, Higham C, Davis J, Eeles R, Stevenson M, O’Sullivan B, Taniere P, Skordilis K, Gabrovska P, Barlier A, Webb SM, Aulinas A, Drake WM, Bevan JS, Preda C, Dalantaeva N, Ribeiro-Oliveira A Jr, Garcia IT, Yordanova G, Iotova V, Evanson J, Grossman AB, Trouillas J, Ellard S, Stratakis CA, Maher ER, Roncaroli F, Korbonits M. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab. 2015 ;100(3):E531–E41. doi:10.1210/jc.2014-3399.CrossRefPubMed

30.

Jamilloux Y, Favier J, Pertuit M, Delage-Corre M, Lopez S, Teissier MP, Mathonnet M, Galinat S, Barlier A, Archambeaud F. A MEN1 syndrome with a paraganglioma. Eur J Hum Genet. 2014;22(2):283–5.CrossRefPubMed

31.

Lee JH, Barich F, Karnell LH, Robinson RA, Zhen WK, Gantz BJ, Hoffman HT. National cancer data base report on malignant paragangliomas of the head and neck. Cancer. 2002;94:730–7.CrossRefPubMed

32.

Rodríguez-Cuevas S, López-Garza J, Labastida-Almendaro S. Carotid body tumors in inhabitants of altitudes higher than 2000 meters above sea level. Head Neck. 1998;20:374–8.CrossRefPubMed

33.

Amato B, Bianco T, Compagna R, Siano M, Esposito G, Buffone G, et al. Surgical resection of carotid body paragangliomas: 10 years of experience. Am J Surg. 2014;207:293–8.CrossRefPubMed

34.

Langerman A, Athavale SM, Rangarajan SV, Sinard RJ, Netterville JL. Natural history of cervical paragangliomas: outcomes of observation of 43 patients. Arch Otolaryngol Head Neck Surg. 2012;138:341–5.CrossRefPubMed

35.

O’Neill S, O’Donnell M, Harkin D, Loughrey M, Lee B, Blair P. A 22-year Northern Irish experience of carotid body tumours. Ulster Med J. 2011;80:133–40.PubMedPubMedCentral

36.

Qin RF, Shi LF, Liu YP, Lei DL, Hu KJ, Feng XH, et al. Diagnosis and surgical treatment of carotid body tumors: 25 years’ experience in China. Int J Oral Maxillofac Surg. 2009;38:713–8.CrossRefPubMed

37.

Sajid MS, Hamilton G, Baker DM, Joint Vascular Research Group. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg. 2007;34:127–30.CrossRefPubMed

38.

Carlson ML, Sweeney AD, Pelosi S, Wanna GB, Glasscock ME 3rd, Haynes DS. Glomus tympanicum: a review of 115 cases over 4 decades. Otolaryngol Head Neck Surg. 2015;152:136–42.CrossRefPubMed

39.

Manolidis S, Shohet JA, Jackson CG, Glasscock ME 3rd. Malignant glomus tumors. Laryngoscope. 1999;109:30–4.CrossRefPubMed

40.

Capatina C, Ntali G, Karavitaki N, Grossman AB. The management of head-andneck paragangliomas. Endocr Relat Cancer. 2013;20:R291–305.CrossRefPubMed

41.

Taïeb D, Kaliski A, Boedeker CC, Martucci V, Fojo T, Adler JR Jr, et al. Current approaches and recent developments in the management of head and neck paragangliomas. Endocr Rev. 2014;35:795–819.CrossRefPubMedPubMedCentral

42.

Kunst HP, Rutten MH, de Mönnink JP, Hoefsloot LH, Timmers HJ, Marres HA, et al. SDHAF2 (PGL2-SDH5) and hereditary head and neck paraganglioma. Clin Cancer Res. 2011;17:247–54.CrossRefPubMed

43.

Capatina C, Ntali G, Karavitaki N, Grossman AB. The management of head-and-neck paragangliomas. Endocr Relat Cancer. 2013;20(5):R291–305. doi:10.1530/ERC-13-0223.CrossRefPubMed

44.

Heinrich MC, Harris AE, Bell WR. Metastatic intravagal paraganglioma. Case report and review of the literature. Am J Med. 1985;78(6 Pt 1):1017–24.CrossRefPubMed

45.

Ferlito A, Milroy CM, Wenig BM, Barnes L, Silver CE. Laryngeal paraganglioma versus atypical carcinoid tumor. Ann Otol Rhinol Laryngol. 1995;104(1):78–83.CrossRefPubMed

46.

Barnes L. Paraganglioma of the larynx. A critical review of the literature. ORL J Otorhinolaryngol Relat Spec. 1991;53:220–34.CrossRefPubMed

47.

de Azevedo-Gamas A, Gloor F. A very unusual case of tumor of the larynx. Unexpected anatomopathologic diagnosis. Ann Otolaryngol Chir Cervicofac. 1968;85:329–35.PubMed

48.

Ferlito A, Barnes L, Wenig BM. Identification, classification, treatment, and prognosis of laryngeal paraganglioma. Review of the literature and eight new cases. Ann Otol Rhinol Laryngol. 1994;103:525–36.CrossRefPubMed

49.

Rüfenacht H, Mihatsch MJ, Jundt K, Gächter A, Tanner K, Heitz PU. Gastric epitheloid leiomyomas, pulmonary chondroma, non-functioning metastasizing extra-adrenal paraganglioma and myxoma: a variant of Carney’s triad. Report of a patient. Klin Wochenschr. 1985;63:282–4.CrossRefPubMed

50.

Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al., EVA Investigators. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers:a multicenter prospective study from the PGL. J Clin Endocrinol Metab. 2013;98:E162–73.CrossRefPubMed

51.

Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med. 2009;266:19–42.CrossRefPubMed

52.

Offergeld C, Brase C, Yaremchuk S, Mader I, Rischke HC, Glasker S, Schmid KW, Wiech T, Preuss SF, Suarez C, Kopec T, Patocs A, Wohllk N, Malekpour M, Boedeker CC, Neumann HP. Head and neck paragangliomas: clinical and molecular genetic classification. Clinics. 2012;67(Suppl 1):19–28.CrossRefPubMedPubMedCentral

53.

HP, Maier W, van Nederveen FH, Suárez C, et al. Genetics of hereditary head and neck paragangliomas. Head Neck. 2014;36:907–16.CrossRef

54.

Burnichon N, Brière JJ, Libé R, Vescovo L, Rivière J, Tissier F, et al. SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet. 2010;19:3011–20.CrossRefPubMedPubMedCentral

Titel: Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas
verfasst von: Michelle D. Williams
Arthur S. Tischler
Publikationsdatum: 28.02.2017
Verlag: Springer US
Erschienen in: Head and Neck Pathology / Ausgabe 1/2017
Elektronische ISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-017-0786-1

Springer Medizin

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Paragangliomas

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Nasal Cavity, Paranasal Sinuses and Skull Base

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Oropharynx

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors

Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Preface

Update From The 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Nasopharynx

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie